Top

Published in:

01-12-2008

Anticoagulant therapy during cardiopulmonary bypass

Authors: Maryam Yavari, Richard C. Becker

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2008

Abstract

The prothrombotic and hemostatic-altering environment that characterizes cardiac surgery in general and cardiopulmonary bypass (CPB) in particular is unparalleled in medicine, causing, in an alarming number of patients, both thrombotic and hemorrhagic events. Fundamentally, the primary objective of anticoagulant therapy during CPB is to prevent thrombin generation and its attendant prothrombotic, proinflammatory, and vascular effects. Though anticoagulation with unfractionated heparin has been the standard of care for more than a half-century for patients undergoing cardiac surgery, inherent limitations, and an unfavorable safety profile will increasingly stimulate the investigation and development of more safe and effective therapies.

Koster A, Fischer T, Gruendel M et al (2003) Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth 17(2):171–175. doi:10.1053/jcan.2003.42 PubMed

Spanier TB, Oz MC, Minanov OP et al (1998) Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg 115(5):1179–1188. doi:10.1016/S0022-5223(98)70419-2 PubMed

Hiramatsu Y, Gikakis N, Gorman JH 3rd et al (1997) A baboon model for hematologic studies of cardiopulmonary bypass. J Lab Clin Med 130(4):412–420. doi:10.1016/S0022-2143(97)90041-X PubMed

Edmunds LH Jr, Colman RW (2006) Thrombin during cardiopulmonary bypass. Ann Thorac Surg 82(6):2315–2322. doi:10.1016/j.athoracsur.2006.06.072 PubMed

Casati V, Gerli C, Franco A et al (2001) Activation of coagulation and fibrinolysis during coronary surgery: on-pump versus off-pump techniques. Anesthesiology 95(5):1103–1109. doi:10.1097/00000542-200111000-00013 PubMed

Boisclair MD, Lane DA, Philippou H et al (1993) Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 82(11):3350–3357PubMed

Hunt BJ, Parratt RN, Segal HC, Sheikh S, Kallis P, Yacoub M (1998) Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg 65(3):712–718. doi:10.1016/S0003-4975(97)01345-3 PubMed

Philippou H, Adami A, Boisclair MD, Lane DA (1995) An ELISA for factor X activaton peptide: application to the investigation of thrombogenesis in cardiopulmonary bypass. Br J Haematol 90:432–437. doi:10.1111/j.1365-2141.1995.tb05170.x PubMed

Burman JF, Chung HI, Lane DA, Philippou H, Adami A, Lincoln JCR (1994) Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet 344:1192–1193. doi:10.1016/S0140-6736(94)90509-6 PubMed

10.

Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH Jr (1996) Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 93(11):2014–2018PubMed

11.

Despotis GJ, Avidan MS, Hogue CW Jr (2001) Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 72(5):S1821–S1831. doi:10.1016/S0003-4975(01)03211-8 PubMed

12.

van Wyk V, Neethling WM, Badenhorst PN, Kotze HF (1998) r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons. J Cardiovasc Surg (Torino) 39(5):633–639

13.

von Segesser LK, Mueller X, Marty B, Horisberger J, Corno A (2001) Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass. Perfusion 16(5):411–416

14.

Vincentelli A, Jude B, Belisle S (2006) Antithrombotic therapy in cardiac surgery. Can J Anaesth 53(6):S89–S102PubMed

15.

Terrell MR, Walenga JM, Koza MJ, Pifarre R (1996) Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass. Ann Thorac Surg 62(2):506–511. doi:10.1016/0003-4975(96)00280-9 PubMed

16.

Cohn LH (2003) Fifty years of open-heart surgery. Circulation 107(17):2168–2170. doi:10.1161/01.CIR.0000071746.50876.E2 PubMed

17.

Hirsh J (2003) Current anticoagulant therapy—unmet clinical needs. Thromb Res 109(suppl 1):S1–S8. doi:10.1016/S0049-3848(03)00250-0 PubMed

18.

Mertzlufft F, Koster A, Hansen R et al (2000) Reliability of the heparin management test for monitoring high levels of unfractionated heparin: in vitro findings in volunteers versus in vivo findings during cardiopulmonary bypass. Anesthesiology 92(6):1594–1602. doi:10.1097/00000542-200006000-00016 PubMed

19.

Dyke CM, Smedira NG, Koster A et al (2006) A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 131(3):533–539. doi:10.1016/j.jtcvs.2005.09.057 PubMed

20.

Woodman RC, Harker LA (1990) Bleeding complications associated with cardiopulmonary bypass. Blood 76(9):1680–1697PubMed

21.

Bevan DH (1999) Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 104(2):208–219. doi:10.1046/j.1365-2141.1999.01182.x PubMed

22.

Hirsh J, Warkentin TE, Shaughnessy SG et al (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119(1):64S–94S. doi:10.1378/chest.119.1_suppl.64S PubMed

23.

Belcher PR, Muriithi EW, Milne EM, Wanikiat P, Wheatley DJ, Armstrong RA (2000) Heparin, platelet aggregation, neutrophils, and cardiopulmonary bypass. Thromb Res 98(4):249–256. doi:10.1016/S0049-3848(99)00243-1 PubMed

24.

Riess FC (2005) Anticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg 17(1):85–96. doi:10.1053/j.semtcvs.2004.12.008 PubMed

25.

Koster A, Pasic M, Bauer M, Kuppe H, Hetzer R (2000) Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function. Ann Thorac Surg 69(1):37–41. doi:10.1016/S0003-4975(99)01289-8 PubMed

26.

Shammas NW (2005) Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev 23(4):345–360PubMed

27.

Riess FC, Potzsch B, Behr I et al (1997) Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model. Eur J Cardiothorac Surg 11(4):739–745. doi:10.1016/S1010-7940(96)01070-6 PubMed

28.

Mannucci L, Gerometta P, Mussoni L et al (1995) One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery. Thromb Haemost 73:356–361PubMed

29.

Khuri SF, Valeri CR, Loscalzo J et al (1995) Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 60(4):1008–1014. doi:10.1016/0003-4975(95)00668-B PubMed

30.

Hyde JA, Chinn JA, Graham TR (1998) Platelets and cardiopulmonary bypass. Perfusion 13(6):389–407PubMed

31.

Merry AF, Raudkivi PJ, Middleton NG et al (2004) Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 77(3):925–931. doi:10.1016/j.athoracsur.2003.09.061 discussion 931PubMed

32.

Hogg PI, Jackson CM (1989) Fibrin monomer protects thrombin from inactivation by heparin–antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 86:3619–3623. doi:10.1073/pnas.86.10.3619 PubMed

33.

Gikakis N, Rao AK, Miyamoto S et al (1998) Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 116(6):1043–1051. doi:10.1016/S0022-5223(98)70057-1 PubMed

34.

Gikakis N, Khan MM, Hiramatsu Y et al (1996) Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation. Circulation 94(suppl 9):II341–II346PubMed

35.

Aiach M, Dreyfus G, Michaud A et al (1984) Low molecular weight (LMW) heparin derivatives in experimental extra-corporeal circulation (ECC). Haemostasis 14(4):325–332PubMed

36.

Gurbuz AT, Elliott WG, Zia AA (2005) Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines. Eur J Cardiothorac Surg 27(1):138–149. doi:10.1016/j.ejcts.2004.09.021 PubMed

37.

Ramakrishna R, Manoharan A, Kwan YL et al (1995) Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low-molecular-weight heparin, dalteparin (Fragmin), and heparinoid, danaparoid (Orgaran). Br J Haematol 91:736–738. doi:10.1111/j.1365-2141.1995.tb05377.x PubMed

38.

Newman PM, Swanson RL, Chong BH (1998) Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 80(2):292–297PubMed

39.

Koster A, Hansen R, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F (2000) Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth 14(3):243–248. doi:10.1016/S1053-0770(00)90117-4 PubMed

40.

Robitaille D, Leclerc JR, Laberge R et al (1992) Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg 103:597–599PubMed

41.

Frederiksen JW (2000) Cardiopulmonary bypass in humans: bypassing unfractionated heparin. Ann Thorac Surg 70:1434–1443. doi:10.1016/S0003-4975(00)01511-3 PubMed

42.

Kincaid EH, Monroe ML, Saliba DL, Kon ND, Byerly WG, Reichert MG (2003) Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 76(1):124–128. doi:10.1016/S0003-4975(03)00190-5 discussion 128PubMed

43.

Meuleman DG, Hobbelen PMJ, Van Dedem G et al (1982) A novel antithrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of pharmacological properties in experimental animal models. Thromb Res 27:353–363. doi:10.1016/0049-3848(82)90082-2 PubMed

44.

Gitlin SD, Deeb GM, Yann C (1998) Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. J Vasc Surg 27:568–575. doi:10.1016/S0741-5214(98)70336-2 PubMed

45.

Wilhelm MJ, Schmid C, Kececioglu D, Mollhoff T, Ostermann H, Scheld HH (1996) Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 61(3):920–924. doi:10.1016/0003-4975(95)01172-2 PubMed

46.

Henny CP, Ten Cate H, Ten Cate JW et al (1985) A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs. J Lab Clin Med 106(2):187–196PubMed

47.

Doherty DC, Ortel TL, de Bruijn N, Greenberg CS, Van Trigt P 3rd (1990) “Heparin-free” cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 73(3):562–565. doi:10.1097/00000542-199009000-00034 PubMed

48.

Koster A, Dyke CM, Aldea G et al (2007) Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 83(2):572–577. doi:10.1016/j.athoracsur.2006.09.038 PubMed

49.

Magnani HN (1993) Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 70:554–561PubMed

50.

Carrier M, Robitaille D, Perrault LP et al (2003) Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial. J Thorac Cardiovasc Surg 125:325–329. doi:10.1067/mtc.2003.103 PubMed

51.

Nutescu EA, Shapiro NL, Chevalier A (2006) New anticoagulant agents: direct thrombin inhibitors. Clin Geriatr Med 22(1):33–56. doi:10.1016/j.cger.2005.09.009 PubMed

52.

Koster A, Chew D, Grundel M, Bauer M, Kuppe H, Spiess BD (2003) Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg 96(2):383–386. doi:10.1097/00000539-200302000-00015 PubMed

53.

Koster A, Merkle F, Hansen R et al (2000) Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg 91(2):265–269. doi:10.1097/00000539-200008000-00003 PubMed

54.

O-Yurvati AH, Laub GW, Southgate TJ, McGrath LB (1994) Heparinless cardiopulmonary bypass with ancrod. Ann Thorac Surg 57:1656–1658PubMed

55.

Kraenzler EJ, Starr NJ, Miller ML, Schiavone WA (1988) Heparinassociated thrombocytopenia: Management of patients for open heart surgery—case reports describing the use of iloprost. Anesthesiology 69:964–967. doi:10.1097/00000542-198812000-00030 PubMed

56.

Vanholder R, Camez A, Veys N et al (1997) Pharmacokinetics of recombinant hirudin in hemodialized end-stage renal failure patients. Thromb Haemost 77:650–655PubMed

57.

Walenga JM, Bakhos M, Messmore HL, Fareed J, Pifarre R (1991) Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann Thorac Surg 51:271–277PubMedCrossRef

58.

Walenga JM, Bakhos M, Messmore HL et al (1991) Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model. Blood Coagul Fibrinolysis 2(1):105–111. doi:10.1097/00001721-199102000-00017 PubMed

59.

Jormalainen M, Vento AE, Wartiovaara-Kautto U, Suojaranta-Ylinen R, Ramo OJ, Petaja J (2004) Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model. J Thorac Cardiovasc Surg 128(2):189–196. doi:10.1016/j.jtcvs.2003.11.058 PubMed

60.

Koster A, Loebe M, Hansen R et al (2000) A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: adaptation of the ecarin clotting time to the act II device. J Thorac Cardiovasc Surg 119(6):1278–1283. doi:10.1067/mtc.2000.106088 PubMed

61.

Conrad KA (1995) Clinical pharmacology and drug safety: lessons from hirudin. Clin Pharmacol Ther 58(2):123–126. doi:10.1016/0009-9236(95)90187-6 PubMed

62.

Manikappa S, Benfield K, Gan TE et al (2005) Heparin-induced thrombocytopenia and the use of r-hirudin during cardiopulmonary bypass. Anaesth Intensive Care 33:388–392PubMed

63.

Latham P, Revelis AF, Joshi GP et al (2000) Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology 92:263–267. doi:10.1097/00000542-200001000-00040 PubMed

64.

Liu H, Fleming NW, Moore PG (2002) Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass. J Clin Anesth 14:452–455. doi:10.1016/S0952-8180(02)00386-0 PubMed

65.

Nuttall GA, Oliver WC, Santrach PJ et al (2003) Patients with a history of type II heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. Anesth Analg 96:344–350. doi:10.1097/00000539-200302000-00009 PubMed

66.

Murphy GS, Marymont JH (2007) Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 21(1):113–126. doi:10.1053/j.jvca.2006.08.011 PubMed

67.

Potzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Muller-Berghaus G (1997) Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass—assessment of the whole blood ecarin clotting time. Thromb Haemost 77(5):920–925PubMed

68.

Wendel HP, Heller W, Gallimore MJ (1996) Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model. Immunopharmacology 32(1–3):57–61. doi:10.1016/0162-3109(96)00009-4 PubMed

69.

Greinacher A, Eichler P, Lubenow N (2003) Anaphylactic reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT). Circulation 108:2062–2065. doi:10.1161/01.CIR.0000096056.37269.14 PubMed

70.

McBane RD 2nd, Hassinger NL, Mruk JS, Grill DE, Chesebro JH (2005) Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin. Thromb Res 116(6):525–532. doi:10.1016/j.thromres.2005.02.010 PubMed

71.

Bates SM, Weitz JL (2000) The mechanism of action of thrombin inhibitors. J Invasive Cardiol 12(suppl F):27–32

72.

Nutescu EA, Wittkowsky AK (2004) Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 38:99–109. doi:10.1345/aph.1D066 PubMed

73.

Swan SK, Hursting MJ (2000) The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20:318–329. doi:10.1592/phco.20.4.318.34881 PubMed

74.

Furukawa K, Ohteki H, Hirahara K et al (2001) The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg 122:1255–1256. doi:10.1067/mtc.2001.116940 PubMed

75.

Edwards JT, Hambly JK, Worrall NK (2003) Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 75:1622–1624. doi:10.1016/S0003-4975(02)04782-3 PubMed

76.

Kieta DR, McCammon AT, Holman WL et al (2003) Hemostatic analysis of a patient undergoing off-pump coronary artery bypass surgery with argatroban anticoagulation. Anesth Analg 96:956–958. doi:10.1213/01.ANE.0000052381.47101.A2 PubMed

77.

Cannon MA, Butterworth J, Riley RD et al (2004) Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery. Ann Thorac Surg 77:711–713. doi:10.1016/j.athoracsur.2003.04.001 PubMed

78.

Bates SM, Weitz JI (1998) Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 82(suppl 1):12P–18P. doi:10.1016/S0002-9149(98)00660-2 PubMed

79.

Koster A, Yeter R, Buz S et al (2005) Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot study. J Thorac Cardiovasc Surg 129(6):1391–1394. doi:10.1016/j.jtcvs.2004.09.016 PubMed

80.

Davis Z, Anderson R, Short D et al (2003) Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg 75:264–265. doi:10.1016/S0003-4975(02)04299-6 PubMed

81.

Measday MA, Zucker ML, Pan CM et al (2005) Optimizing management of hirudin anticoagulation. J Extra Corpor Technol 37:66–70PubMed

82.

Jabr K, Johnson JH, McDonald MH et al (2004) Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. J Extra Corpor Technol 36:174–177PubMed

83.

Koster A, Spiess B, Jurmann M et al (2006) Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the “EVOLUTION OFF” trial. Anesth Analg 103(3):540–544. doi:10.1213/01.ane.0000226098.95698.0f PubMed

84.

Koster A, Spiess B, Chew DP et al (2004) Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardiol 93(3):356–359. doi:10.1016/j.amjcard.2003.10.021 PubMed

85.

Stratmann G, deSilva AM, Tseng EE et al (2004) Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 98(6):1635–1639PubMed

86.

Koster A, Chew D, Grundel M et al (2003) An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg 96:1316–1319. doi:10.1213/01.ANE.0000057605.61063.55 PubMed

87.

Spiess BD, DeAnda A, McCarthy HL et al (2006) Case 1-2006. Off-pump coronary artery bypass surgery anticoagulation with bivalirudin: a patient with HIT type II and renal failure. J Cardiothorac Vasc Surg 20:106–111

88.

Vasquez JC, Vichiendilokkul A, Mahmood S et al (2002) Anticoagulationwith bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg 74:2177–2179. doi:10.1016/S0003-4975(02)04125-5 PubMed

89.

Bott JN, Reddy K, Krick S (2003) Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia. Ann Thorac Surg 76:273–275. doi:10.1016/S0003-4975(03)00144-9 PubMed

90.

Smedira NG, Dyke CM, Koster A et al (2006) Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 131:686–692. doi:10.1016/j.jtcvs.2005.10.049 PubMed

91.

Veale JJ, McCarthy HM, Palmer G, Dyke CM (2005) Use of bivalirudin as an anticoagulant during cardiopulmonary bypass. J Extra Corpor Technol 37(3):296–302PubMed

92.

Vasquez JC, Vichiendilokkul A, Mahmood S, Baciewicz FA Jr (2002) Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg 74(6):2177–2179. doi:10.1016/S0003-4975(02)04125-5 PubMed

93.

Huebler M, Koster A, Buz S et al (2006) Cardiopulmonary bypass for complex cardiac surgery using bivalirudin anticoagulation in a patient with heparin antibodies. J Card Surg 21(3):286–288. doi:10.1111/j.1540-8191.2006.00233.x PubMed

94.

Hoffman M, Monroe DM, Oliver JA, Roberts HR (1995) Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 86(5):1794–1801PubMed

95.

Bauer KA, Kass BL, Cate HT, Hawiger JJ, Rosenberg RD (1990) Factor IX is activated in vivo by the tissue factor mechanism. Blood 76(4):731–736PubMed

96.

Osterud B, Rapaport SI (1977) Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 74(12):5260–5264. doi:10.1073/pnas.74.12.5260 PubMed

97.

Dyke CK, Steinhubl SR, Kleiman NS et al (2006) First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114(23):2490–2497. doi:10.1161/CIRCULATIONAHA.106.668434 PubMed

98.

Benedict CR, Ryan J, Wolitzky B et al (1991) Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 88(5):1760–1765. doi:10.1172/JCI115495 PubMed

99.

Nimjee SM, Keys JR, Pitoc GA, Quick G, Rusconi CP, Sullenger BA (2006) A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 14:408–415PubMed

100.

Rusconi CP, Scardino E, Layzer J et al (2002) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419(6902):90–94. doi:10.1038/nature00963 PubMed

101.

Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC (2008) A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost 6(5):789–796. doi:10.1111/j.1538-7836.2008.02932.x PubMed

102.

Joachimi A, Mayer G, Hartig JS (2007) A new anticoagulant–antidote pair: control of thrombin activity by aptamers and porphyrins. J Am Chem Soc 129(11):3036–3037. doi:10.1021/ja0677822 PubMed

103.

Neeper MP, Waxman L, Smith DE et al (1990) Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa. J Biol Chem 265(29):17746–17752PubMed

104.

Fioravanti C, Burkholder D, Francis B, Siegl PK, Gibson RE (1993) Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis. Thromb Res 71(4):317–324. doi:10.1016/0049-3848(93)90200-8 PubMed

105.

Messmore HL, Wehrmacher WH, Coyne E, Fareed J (2004) Heparin to pentasaccharide and beyond: the end is not in sight. Semin Thromb Hemost 30(Suppl 1):81–88. doi:10.1055/s-2004-823006 PubMed

106.

Samama MM, Gerotziafas GT (2003) Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 109(1):1–11. doi:10.1016/S0049-3848(03)00030-6 PubMed

107.

Lee AY, Vlasuk GP (2003) Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med 254(4):313–321. doi:10.1046/j.1365-2796.2003.01224.x PubMed

108.

Peng ZC, Cai X, Zhang YG et al (2007) A novel anti-tissue factor monoclonal antibody with anticoagulant potency derived from synthesized multiple antigenic peptide through blocking FX combination with TF. Thromb Res 121(1):85–93. doi:10.1016/j.thromres.2007.03.001 PubMed

109.

Lev EI, Marmur JD, Zdravkovic M et al (2002) Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study. Arterioscler Thromb Vasc Biol 22(6):1036–1041. doi:10.1161/01.ATV.0000019732.25208.B8 PubMed

110.

Matyal R, Mahmood F, Park KW (2005) Tifacogin, recombinant tissue factor pathway inhibitor. Int Anesthesiol Clin 43(2):135–144. doi:10.1097/01.aia.0000157499.41843.a3 PubMed

Title: Anticoagulant therapy during cardiopulmonary bypass
Authors: Maryam Yavari
Richard C. Becker
Publication date: 01-12-2008
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-008-0280-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Bleeding after antithrombotic therapy in patients with acute ischemic heart disease

Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics?

Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction

Superior vena cava filters: hindsight, insight and foresight

Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history

The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials